Episode Details

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/emerging-agents-in-pulmonary-arterial-hypertension-10829

Program Description

This enduring educational activity provides a comprehensive update on late stage agents being researched for the management of pulmonary arterial hypertension (PAH). Led by expert faculty, the program shifts the clinical focus from traditional vasodilators to novel investigational therapies that directly target the underlying cellular pathways responsible for pulmonary vascular remodeling and disease progression. Clinicians will gain critical insights into the mechanisms of action, latest clinical trial data, and real-world practice implications of these emerging therapeutic classes to better address unmet needs in contemporary care.

At the conclusion of this activity, participants should be better able to:

Discuss clinical trial data and potential clinical utility of emerging agents in PAH.

Accredited Providers

The National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP).

Accreditation Statement

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 

Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

Intended Audience

Pulmonology clinicians (physicians, nurse practitioners, and physician associates), cardiology clinicians, and primary care clinicians caring for patients with or at risk for PAH.

Faculty

Ioana Preston, MD
Director Pulmonary Hypertension Center
Lahey Hospital and Medical Center
UMASS Chan Medical School
Burlington, MA

Dr. Preston has disclosed the following financial relationships:
Consultant: Gossamer Bio, Insmed, Janssen Pharmaceuticals, Keros Therapeutics, Liquidia Technologies, Merck & Co./Acceleron Pharma, Respira Technologies, United Therapeutics Corporation
Contracted Research: Gossamer, Janssen Pharmaceuticals, Merck & Co./Acceleron Pharma, Novartis, United Therapeutics Corporation
Data and Safety Monitoring Board (DSMB): Tectonic Therapeutic

All of her disclosures are related to PH.

Jean Elwing, MD
Professor of Medicine, University of Cincinnati College of Medicine
Director, Pulmonary Hypertension Program, University of Cincinnati 
Pulmonary, Critical Care and Sleep Medicine
Cincinnati, OH

Dr. Elwing has disclosed the following financial relationships:
Consultant: Gossamer Bio (pulmonary hypertension), Insmed (pulmonary hypertension), Liquidia (pulmonary hypertension), United Therapeutics (pulmonary hypertension)
Speaker: Merck (pulmonary hypertension)
Contracted Research: Acceleron/Merck (pulmonary hypertension), Gossamer Bio (pulmonary hypertension), Inhibikase (pulmonary hypertension), Insmed (pulmonary hypertension), Lung LLC (pulmonary hypertension), Novartis (pulmonary hypertension), NS Pharma (pulmonary hypertension), Pharmosa/Liquidia (pulmonary hypertension), Pulmovant (pulmonary hypertensi